Lives unaffected by cystic fibrosis

DRUG DEVELOPMENT PIPELINE

Back to the Drug Development Pipeline

ETD002

Phase One

Phase One

Therapeutic Approach

Mucociliary Clearance

ETD002 is a compound designed to increase the activity the activity of TMEM16A, a chloride channel found on the surfaces of airway cells. Similar to the CFTR channel, the TMEM16A channel helps regulate the amount of salt and fluids on the airway surface. Increasing the activity of TMEM16A ay help increase the amount of fluid within the airways to improve mucus clearance.

Status

A phase 1 study to test the safety of ETD002 in healthy participants is underway.

Sponsor

This program is sponsored by Roche (Genentech) and partially funded by the Cystic Fibrosis Foundation.



Contact us about ETD002 >